BioNexus Gene Lab Corp. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-14: Disclosure Rule10b51Arr Adopted; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Rule10b51Arr Terminated; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Adopted; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Terminated; Period 2026-01-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-14 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Insider Trading Policies Proc Not Adopted | 2026-01-01..2026-06-30 | The Company is correcting two statements in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Annual Report described Mr. Su-Leng Tan Lee as the Chief Executive Officer of Fidelion Diagnostics Pte. Ltd. The Annual Report also stated that his employment agreement with th… | |
| 2026-08-14 10-Q | Trading Arrangement Individual Title | 2026-01-01..2026-06-30 | Chief Executive Officer | |
| 2026-08-14 10-Q | Trading Arrangement Individual Name | 2026-01-01..2026-06-30 | Mr. Su-Leng Tan Lee | |
| 2026-05-15 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-14 10-K | Rule10b51Arr Adopted | 2025-01-01..2025-12-31 | No | |
| 2026-04-14 10-K | Rule10b51Arr Terminated | 2025-01-01..2025-12-31 | No | |
| 2026-04-14 10-K | Non Rule10b51Arr Adopted | 2025-01-01..2025-12-31 | No | |
| 2026-04-14 10-K | Non Rule10b51Arr Terminated | 2025-01-01..2025-12-31 | No | |
| 2025-11-14 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-09-30 | No | |
| 2025-08-18 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-06-30 | No | |
| 2025-08-18 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-06-30 | No | |
| 2025-08-18 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-06-30 | No | |
| 2025-08-18 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-06-30 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-04-15 10-K | Rule10b51Arr Adopted | 2024-01-01..2024-12-31 | No | |
| 2025-04-15 10-K | Rule10b51Arr Terminated | 2024-01-01..2024-12-31 | No | |
| 2025-04-15 10-K | Non Rule10b51Arr Adopted | 2024-01-01..2024-12-31 | No | |
| 2025-04-15 10-K | Non Rule10b51Arr Terminated | 2024-01-01..2024-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |